PTG Poltreg S.A.
20.00PLN-1.48%Mkt Cap: 30.42M $P/E: —Today
Poltreg S.A., a biotechnology company, researches and develops therapies for autoimmune diseases in Poland. Its product pipeline includes PTG-OO7 + Rituximab which is in phase II clinical trial to treat presymptomatic T1…
Industry Peers
Biotechnology$127.85BUSDP/E 29.4
$75.86BUSD
$75.69BUSDP/E 18.2
$57.51BUSDP/E 35.1
$55.24BUSDP/E 36.1
$44.29BUSD
$41.63BUSDP/E 17.7
$40.51BUSDP/E 63.9
$33.03BUSDP/E 30.7
$29.40BUSDP/E 38.3
$25.80BUSD
$24.34BUSD
$24.27BUSD
$23.37BUSDP/E 14.7
$21.61BUSDP/E 29.3
$21.69BUSDP/E 27.4
$15.30BUSDP/E 16.1
$14.99BUSDP/E 17.8
$14.47BUSDP/E 18.4
$13.37BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
NNauka w Polsce | ||